Our TIRZEPATIDE 60 pen holds 60 mg of tirzepatide in 3 ml, pre-loaded and ready to use, and is in stock and shipping now. Tirzepatide is the most thoroughly trialled compound we sell by a wide margin, and it is also the one where the gap between the authorised medicine and our pen matters most. Both things are true at once, and this page states both: what the 60 mg figure means, what the trials measured, how the pen differs from the pharmacy product, and what arrives in the box.
What 60 mg means on a pre-loaded pen
The 60 mg on the label is the total amount of tirzepatide in the 3 ml cartridge, a concentration of 20 mg/ml. It is not a dose, and it is not a claim about how long the pen lasts. The content is fixed when the cartridge is filled; the dial draws measured increments from that one reservoir, and nothing about the pen prescribes a schedule.
Pre-loaded means the peptide is already in solution. A freeze-dried vial has to be reconstituted with bacteriostatic water, drawn into a syringe and calculated at the point of use; a pen skips all three steps, which removes the places where handling most often goes wrong. We set the two formats side by side at pen vs vial and explain the skipped step itself at reconstitution and why pens skip it.
What tirzepatide is
Tirzepatide is a dual agonist: one molecule that acts like both GIP and GLP-1, the two gut hormones released after a meal, by binding their receptors in the pancreas, the brain and elsewhere (European Medicines Agency. Mounjaro EPAR.). Earlier compounds in the class, semaglutide among them, act on GLP-1 alone; the added GIP activity is what defines tirzepatide (what is tirzepatide?). Retatrutide goes one receptor further and adds glucagon, which makes it a triple agonist rather than a dual one (Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med 2023. PMID 37366315). We sell that compound as well, as RETATRUTIDE 32 and 64, and the two are set against each other at retatrutide vs tirzepatide. They are different mechanisms, not the same mechanism in different amounts.
What SURMOUNT-1 reported
The trial programmes behind tirzepatide are large, completed and published, which is unusual for anything on this site. SURMOUNT is the obesity programme: four global Phase 3 trials with percentage change in body weight as the primary end point in each (le Roux CW et al. Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. Obesity (Silver Spring) 2023. PMID 36478180).
SURMOUNT-1 randomised 2,539 adults with obesity or overweight and no diabetes to 5 mg, 10 mg or 15 mg of tirzepatide or placebo for 72 weeks, including a 20-week dose-escalation period; at week 72 the mean change in body weight was −15.0% on 5 mg, −19.5% on 10 mg and −20.9% on 15 mg, and −3.1% on placebo, with P<0.001 for every comparison (Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022. PMID 35658024; NCT04184622). Among the 1,032 who also had prediabetes, treatment ran on to 176 weeks: weight change was −12.3%, −18.7% and −19.7% against −1.3% on placebo, and 1.3% of those on tirzepatide had progressed to type 2 diabetes against 13.3% on placebo (Jastreboff AM et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med 2025. PMID 39536238).
Both trials were funded by Eli Lilly. That is worth stating as a matter of course rather than as an insinuation: industry funding is normal for a development programme of this size, and the registration and publication record is what makes the results assessable. The figures are group means from supervised trials with slow upward titration and a lifestyle programme alongside the drug. They describe the molecule under those conditions and are not a forecast for you.
The second programme, and the head-to-head
SURPASS studied tirzepatide in type 2 diabetes and is a separate body of work from SURMOUNT. Its second trial put tirzepatide directly against semaglutide: 1,879 patients for 40 weeks, tirzepatide at 5 mg, 10 mg or 15 mg against semaglutide at 1 mg, with tirzepatide noninferior and superior on glycated haemoglobin and a further 1.9 to 5.5 kg of weight lost (Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021. PMID 34170647). The comparator there was semaglutide’s 1 mg diabetes dose, which is the main caveat on that result; the full picture is at tirzepatide vs semaglutide. Between SURMOUNT and SURPASS, tirzepatide has a two-indication evidence base that essentially nothing else in our range has, and that is precisely why it holds a marketing authorisation and the others do not.
Adverse events, and what we do not publish
Gastrointestinal adverse events, chiefly nausea, diarrhoea, vomiting and constipation, are the characteristic pattern for this class. In SURMOUNT-1 they were dose-related and occurred mostly during dose escalation, which is why the trials raised the dose over months rather than starting at the target. We do not publish a dosing schedule. The trial regimens are public in the papers above, and dose selection, titration pace and monitoring belong with a clinician who knows your history. That applies with particular force here, because an authorised product with an approved schedule exists and a clinician can prescribe it.
What the published record does not contain is any study of tirzepatide supplied in this form or through this route. The trial figures describe the molecule; they do not describe this pen.
This pen is not Mounjaro
Tirzepatide is authorised in the EU as Mounjaro, a prescription-only medicine given by prefilled pen and injected once a week (European Medicines Agency. Mounjaro EPAR.). Its authorised presentations are single-dose pre-filled pens and vials at six strengths, 2.5, 5, 7.5, 10, 12.5 and 15 mg, each in 0.5 ml, plus a multi-dose KwikPen whose cartridge is labelled by the dose it delivers rather than by its total content (European Medicines Agency. Mounjaro EPAR: all authorised presentations.). Every one of those products comes with an approved dose, a summary of product characteristics, a pharmacist and post-marketing surveillance collecting adverse events.
Our pen is not that product. It contains the same active compound, 60 mg in 3 ml, labelled by total content, independently tested per batch, and sold without any of those safeguards. Buying the active ingredient of an authorised medicine outside its authorised route means the trial results above still describe the molecule while none of the safeguards that surrounded those results are present. Anyone presenting a pen like ours as equivalent to the pharmacy product is misdescribing it; we set out the distinction in full at why these compounds are not EMA-authorised.
| Mounjaro | TIRZEPATIDE 60 |
|---|
| The label states | A dose, 2.5 to 15 mg | Total content, 60 mg in 3 ml |
| Format | Single-dose pens, vials, multi-dose KwikPen | One multi-dose pen, 3 ml |
| Supplied through | A pharmacy, on prescription | Our site, with a per-batch certificate |
What arrives, and how it travels
The parcel holds the pen, eight standard threaded pen needles, a printed guide and a verification sticker, in insulated packaging with a cooling element and a temperature indicator, inside discreet outer packaging. The certificate for your batch is reached by scanning the QR code on the pen or from the certificate index, as a plain PDF with no account needed. Every batch is tested by an independent laboratory for identity by mass spectrometry, purity by HPLC and sterility; the certificate shows the purity figure and the cartridge concentration.
Order before 12:00 on a business day and the parcel leaves our Czech dispatch point the same day. Delivery takes 3 to 5 business days across the EU markets we serve, tracked door to door, with the tracking link by email and WhatsApp updates if you opt in. Because dispatch is inside the EU, there are no customs charges and no import paperwork. The pen travels at 2 to 8 °C from dispatch to your refrigerator, and the indicator in the box tells you whether it stayed there (cold-chain shipping). Shipping cost is shown at checkout before you pay. Five pens in one order, in any mix of compounds, bring a 10% reduction on the pen total and ten pens 15%, applied automatically at checkout. TIRZEPATIDE 60 is also listed with our NAD+ pen as the Lean Stack, and everything we sell under the weight-loss goal is on one page.
What to check on arrival, and returns
Three things are worth a look before the pen goes in the fridge. The temperature indicator should show no excursion; if it does, photograph it before doing anything else. The pen should be in its original sealed packaging with no sign of tampering. And the batch number on the pen should match the batch on the certificate you open from the QR code, with the concentration line reading 60 mg per 3 ml.
Unopened, unused pens in their original sealed packaging can be returned within 30 days of delivery for a full refund to the original payment method, processed within 5 business days of approval; opened or used pens cannot be returned. A pen that arrives damaged, broken or not working, or with a breached temperature indicator, is replaced free of charge once you send photos or a short video of the fault. The full terms are at returns.
